Nat Med by Ray, Nancy B. et al.
Dynamic regulation of cardiolipin by the lipid pump, ATP8b1, 
determines the severity of lung injury in experimental bacterial 
pneumonia
Nancy B. Ray#1, Lakshmi Durairaj#1, Bill B. Chen2, Bryan J. McVerry2, Alan J. Ryan1, 
Michael Donahoe2, Alisa K. Waltenbaugh2, Christopher P. O’Donnell2, Florita C. 
Henderson1, Christopher A. Etscheidt1, Diann M. McCoy1, Marianna Agassandian1, Emily 
C. Hayes-Rowan2, Tiffany A. Coon2, Phillip L. Butler3, Lokesh Gakhar3, Satya N. Mathur1, 
Jessica C. Sieren1, Yulia Y. Tyurina4, Valerian E. Kagan4, Geoffrey McLennan1,5,6, and 
Rama K. Mallampalli2,7
1Departments of Internal Medicine, University of Iowa, Iowa City, IA 52242
2Departments of Internal Medicine, Acute Lung Injury Center of Excellence, University of 
Pittsburgh, Pittsburgh, PA 15213
3Departments of Biochemistry, University of Iowa, Iowa City, IA 52242
4Center for Free Radical and Antioxidant Health, Department of Environmental and Occupational 
Health, University of Pittsburgh, Pittsburgh, PA 15219
5Department of Radiology, University of Iowa, Iowa City, IA 52242
6Department of Biomedical Engineering, University of Iowa, Iowa City, IA 52242
7Veteran’s Affairs Pittsburgh Healthcare System, Pittsburgh, PA 15206
# These authors contributed equally to this work.
Abstract
Pneumonia remains the leading cause of infectious deaths and yet fundamentally new conceptual 
models underlying its pathogenesis have not emerged. Patients and mice with bacterial pneumonia 
have marked elevations of cardiolipin in lung fluid, a rare, mitochondrial-specific phospholipid 
that potently disrupts surfactant function. Intratracheal cardiolipin in mice recapitulates the clinical 
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
*Address Correspondence to: Rama K. Mallampalli, M.D., Department of Internal Medicine, PACCM, NW628 Montefiore, 3459 
Fifth Avenue, Pittsburgh, PA 15213, Telephone: 412-692-2112, Fax: 412-692-2260, mallampallirk@upmc.edu. 
Author Contributions
N.B.R designed and executed CL-ATP8b1 binding, in vitro imaging, immunological studies, and wrote the manuscript. L.D. edited 
the manuscript, conducted the human studies. B.B.C. performed in vitro (CL uptake, biochemical and molecular) experiments, and all 
animal studies. B.J.M. and M.D. contributed to human studies and statistical analyses. A.K.W., T.A.C., M.A., P.L.B., F.C.H., S.N.M. 
performed in vitro studies. A.J. R. and C.P.O. performed mouse studies. D.M., E.H-R., and C.E. conducted CL analysis. L.G. 
conducted surfactant studies. J.C.S. and G.M. designed and conducted in vivo imaging. V.E.K. designed and executed mass 
spectrometry of CL with assistance from Y.Y.T. and V.E.K provided editorial suggestions. R.K.M. revised the manuscript and 
directed the study.
Competing financial interests
The authors declare no competing financial interests.
HHS Public Access
Author manuscript
Nat Med. Author manuscript; available in PMC 2015 July 13.
Published in final edited form as:













phenotype of pneumonia including impaired lung mechanics, modulation of cell survival and 
cytokine networks, and lobar consolidation. We have identified and characterized the activity of a 
novel cardiolipin transporter, ATP8b1, a mutant version of which is associated with severe 
pneumonia in humans and mice. ATP8b1 bound and internalized cardiolipin from extracellular 
fluid via a basic residue-enriched motif. Administration of cardiolipin binding motif peptide or 
ATP8b1 gene transfer in mice lessened lung injury and improved survival. The results unveil a 
new paradigm whereby ATP8b1 is a cardiolipin importer but its capacity to remove cardiolipin 
from lung fluid is exceeded during inflammation or ATP8b1 inefficiency. This discovery opens 
the door for new therapeutic strategies directed at modulating cardiolipin levels or its molecular 
interactions in pneumonia.
Introduction
Pneumonia is the leading cause of death in the US from infectious causes and it is second 
(only to childbirth) for hospital admission1. Thus, it remains a major cause of morbidity and 
contributes significantly to healthcare costs in both the community and hospitalized patients. 
The pathobiology of bacterial pneumonia after infection with highly virulent pathogens 
(Streptococcus pneumoniae, Staphylococcus aureus, H. influenzae and E. coli) typically 
involves neutrophilic lung infiltration and a robust host immune response leading to severe 
ventilatory abnormalities. Several microbial virulence and host factors partake in the 
progression of pulmonary injury 2. Despite decades of intensive study, there has been a lack 
of fundamentally new biological mechanisms that have emerged with regard to the 
pathobiology of bacterial pneumonia. Consequently, there has been an over-reliance on the 
use of broad spectrum antibiotics in severe infection with the emergence of multi-drug 
resistant strains.
In the process of identifying mediators of pulmonary infection, we analyzed patients with 
bacterial pneumonia and discovered elevated levels of the phospholipid, cardiolipin (CL) in 
lung fluid. CL is typically a minor component of pulmonary lavage fluid and comprises only 
~1-2% of alveolar surfactant, a surface-tension lowering material enriched with 
phosphatidylcholine and key apoproteins that is secreted into the airways by type II alveolar 
epithelia 3. Elevated CL levels are seen in lung injury models 4,5. However, the biological 
significance and mechanisms for changes in CL content remains enigmatic. The findings of 
very low CL levels in lung fluid under native conditions suggest the existence of control 
mechanisms that tightly regulate CL availability within the airways or extracellular fluid.
One population at increased risk for pneumonia includes patients with progressive familial 
intrahepatic cholestasis type 1 (PFIC1, or Byler Disease) 6,7. Pneumonia and respiratory 
symptoms were seen in 13% and 26% of PFIC1 patients 6,8. PFIC1 patients have mutations 
in the P-type ATPase transmembrane lipid pump, ATP8b1. Type 4 P-type ATPases maintain 
lipid balance by translocating phospholipids from the outer to inner leaflets of membrane 
bilayers. ATP8b1 translocates phosphatidylserine (PS) from the outer to inner membrane in 
cells, is highly expressed in apical epithelial membranes, and is present in various human 
tissues 7. The observation that patients with PFIC1 are prone to respiratory infection coupled 
with the ability of ATP8b1 to transport phospholipids across cellular membranes led us to 
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hypothesize that ATP8b1 is an authentic CL import protein. To test this hypothesis, we used 
ATP8b1 defective mice that harbor a prototypic PFIC1 mutation (G308V) observed in 
patients with severe PFIC1.
In this study, we discovered that CL is elevated in lung fluid of patients with pneumonia and 
that the lipid is a highly potent surfactant inhibitor that disrupts lung structure and function. 
The abundance of CL in lung fluid is regulated by ATP8b1, which effectively binds and 
internalizes the lipid in lung epithelia via domain specific interactions. ATP8b1 mutant mice 
have elevated CL levels in lung fluid and were prone to bacterial induced lung injury. These 
results provide a novel conceptual model for bacterial pneumonia where ATP8b1 serves as a 
molecular transporter that evacuates an injurious bioactive lipid from distal airways to 
preserve pulmonary homeostasis.
Results
CL is elevated in pneumonitis
CL was quantitated in tracheal aspirates from critically ill subjects with non-pulmonary 
illnesses (n=five), clinically diagnosed pneumonia (n=17), or congestive heart failure (CHF) 
(n=six, Supplementary Table I). Control patients with non-pulmonary illnesses included 
those requiring mechanical ventilation for liver failure, hemolysis elevated liver enzymes 
low platelets (HELLP) syndrome, Guillain-Barre syndrome, renal failure, and 
gastrointestinal tract bleeding. Subjects with pneumonia were identified as having new or 
changing radiographic pulmonary infiltrates, increasing sputum quantity or change in 
sputum character, and clinical features such as fever, elevated white blood cell count and 
hypoxemia without dependence upon sputum culture results or distinction between 
community or hospital acquisition. No bacterial growth was detected in 39% (7/17) of 
subjects with pneumonia while tracheal aspirates grew Streptococcus pneumoniae in four 
subjects, Pseudomonas aeruginosa and Staphylococcus aureus in three subjects each, and 
Haemophilus influenza in one subject. 90% (26/28) of all subjects were on broad-spectrum 
antibiotics on the day of tracheal aspirate collection (Supplementary Table. 1). Subjects with 
pneumonia had significantly higher levels of CL (median=12.9 Mol%) in tracheal aspirates 
compared to subjects with non-pulmonary diagnoses (~9.7 fold) or CHF (~6 fold, Kruskal-
Wallis P=0.0007, Fig. 1a). Importantly, CL levels did not correlate with culture status, 
bacterial pathogen, duration of mechanical ventilation, gender, or age (Supplementary Fig. 
1).
Mice were also infected with strains of H. influenzae or E. coli that cause pneumonia 9,10. 
Bronchoalveolar lavage (BAL) fluid from infected mice had greater levels of CL than BAL 
isolated from uninfected mice (Fig. 1b). To assess if elevated CL levels were due to reduced 
cellular uptake, primary mouse type II lung epithelia were cultured with [3H] CL. Infection 
with H. influenzae or E. coli resulted in significantly reduced cellular uptake of [3H] CL 
(Fig. 1c). Thus, CL is increased in lung fluid of both patients and animal models with 
pneumonitis and this may be due to decreased epithelial uptake of the phospholipid.
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CL impairs lung structure, function, and cell viability
Phospholipids (CL, LPC [lysophosphatidylcholine], PS [phosphatidylserine]) were 
incorporated into Infasurf (a commercial apoprotein containing surfactant) to generate lipid 
vesicles that were used to assay surface-tension (Fig. 2a). Lipids were also extracted from 
Infasurf to generate protein-deficient preparations that were reconstituted with phospholipids 
for testing (Fig. 2b). Unlike PS, increasing CL concentrations (> 3 Mol%) resulted in 
increased surface-tension. CL impaired surface-activity to a greater extent than LPC, a 
positive control 11. These adverse effects of CL were more pronounced when testing lipid 
extracts devoid of surfactant-associated apoproteins (Fig. 2b). Mice given intratracheal (i.t.) 
CL had significantly decreased lung compliance and increased elastance and resistance 
compared to controls (Fig. 2c-f). CL also increased BAL protein concentration 
(Supplementary Fig. 2a), differentially altered surfactant proteins (Supplementary Fig. 2b), 
reduced γ-interferon and IL-2 and increased IL-10 (Supplementary Fig. 2c,d), but did not 
affect the distribution of various inflammatory cells (Supplementary Fig. 2e) in vivo. Thus, 
CL in lung fluid adversely affects lung mechanics by greatly impairing surfactant activity. 
The lipid also modulates expression of cytokine networks that could impact lung stability.
Mice were subjected to live imaging of lungs by micro CT scanning (Fig. 3a). Compared to 
diluent, mice given CL (50 nmol) had more prominent markings in parenchyma with 
scattered patchy areas of alveolar consolidation (arrows). These abnormalities were more 
severe after high doses of CL. Histological analysis identified areas of alveolar infiltration 
and appearance of foamy cells within alveoli (Fig. 3a, lowest, mid panel, arrows). High dose 
CL produced edema and disruption of alveolar lining cells (Fig. 3a, lower right panels, Fig. 
3b,c) that contributed to fatality of mice within 2-3 h. CL activated the apoptotic program in 
cells (Fig. 3d, left) and in tissue (Fig. 3d, right panel) and it decreased cell viability (Fig. 3e) 
and increased cell toxicity (Fig. 3f).
ATP8b1 is an alveolar epithelial CL importer
Because CL is internalized by alveolar cells, we hypothesized that cells would express an 
import protein that regulates CL levels in lung fluid. ATP8b1 was a candidate protein as it 
internalizes phospholipids and patients with ATP8b1 defects are prone to pneumonia 8. 
Type II cells had high levels of ATP8b1 compared to macrophages or fibroblasts 
(Supplementary Fig. 3a, [inset]), ATP8b1 expression was regulated (Supplementary Fig. 
3b), and it exhibited surface expression (Supplementary Fig. 3c). Lentiviral ATP8b1 
expressing cells had higher levels of mRNA and protein expression coupled with a robust 
increase in the uptake of fluorescent (nitrobenzoxadiazole [NBD]) labeled NBD-CL or 
NBD-PS (positive control) compared to non-transduced cells (Supplementary Fig. 3d, Fig. 
4a, b). ATP8b1 overexpressing cells had greater fluorescence on both the cell surface and 
inside the cells, indicating that the NBD-CL was located on the plasma membrane and 
within the cytoplasm. Although ATP8b1 internalized CL, it did not enhance GFP-labeled E. 
coli uptake (Supplementary Fig. 3e).
Mice were also administered adenovirus (Ad5) expressing ATP8b1 or empty adenovirus 
prior to E. coli infection. Mice infected with E. coli at 1 × 106 CFU/mouse cleared the 
pathogens by 48 h of analysis. These mice exhibited decreased BAL macrophages with a 
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neutrophilic infiltrate typical of pneumonia, a profile not affected by Ad5-ATP8b1 gene 
transfer (Supplementary Fig. 4a). Ad5 alone or Ad5 encoding ATP8b1 tended to have high 
BAL protein concentrations associated with release of pro-inflammatory cytokines after 
bacterial infection (Supplementary Fig. 4b,c). ATP8b1 gene delivery before E. coli infection 
also reduced collectins, surfactant protein A (SP-A) and surfactant protein D (SP-D), but did 
not affect surfactant protein B (SP-B), the latter essential for surfactant activity 
(Supplementary Fig. 4d). Importantly, ATP8b1 gene delivery effectively increased pump 
levels, reduced CL levels, and reversed E. coli induced impairment of lung mechanics (Fig. 
4c,d, Supplementary Fig. 4e) compared to infected mice given Ad5. ATP8b1 gene transfer 
did not reduce apoptosis after bacterial infection (Fig. 4e). Thus, the primary mechanism for 
beneficial effects of increased ATP8b1 expression is via reduced CL availability, thereby 
preserving surfactant function and improving lung mechanics. These effects were sufficient 
to result in increased survival of mice (Fig. 4f).
Additional loss-of-function studies were performed using siRNA and ATP8b1 mutant mice 
that harbor a single amino acid substitution (Gly308→Val) resulting in an apparent defect in 
PS importability 12,13. ATP8b1 siRNA produced a significant decrease in CL uptake and 
selectively reduced immunoreactive ATP8b1 compared to control RNA (Fig. 5a). HaeIII 
restriction digest fragment patterns were used to genotype mutant, wild-type, and 
heterozygous mice revealing that mutants lacked 500 bp and 300 bp digest fragments (Fig. 
5b). We detected low level ATP8b1 expression in mutant liver and lung compared to wild-
type tissues (Fig. 5c). ATP8b1 mutant mice had significantly higher BAL CL versus wild-
type littermates (Fig. 5d). Consistent with ATP8b1’s inability to alter bacterial uptake, 
bacterial loads did not differ between ATP8b1 mutant and wild-type mice (Supplementary 
Fig. 5a). Both ATP8b1 defective and wild-type littermates exhibited no differences in BAL 
protein content (Supplementary Fig. 5b), wet/dry lung weight ratios (Supplementary Fig. 
5c), or cellular inflammation (Supplementary Fig. 5d) after infection. Interestingly, ATP8b1 
defective mice exhibited a blunted cytokine response to Th1 cytokines (interferon-γ, TNF-α, 
IL-β) compared to wild-type littermates after E. coli infection (Supplementary Fig. 6a,b) 
which may be secondary to increased expression of SP-A and SP-D (Supplementary Fig. 
6c)14,15. Primary type II cells isolated from ATP8b1 mutant mice exhibited a blunted 
response with regard to NBD-CL uptake compared to cells isolated from wild-type 
littermates (Fig. 5e). Mutant mice also had impaired biophysical properties compared to 
wild-type mice particularly following E. coli infection (Figs. 5f,g, Supplementary Fig. 6d). 
Although mutant mice also were more prone to apoptosis (Fig. 5h), there was no significant 
difference in mortality between ATP8b1 mutant and wild-type mice with infection (Fig. 5i). 
Collectively, these studies strongly suggest that ATP8b1 is a bona fide alveolar epithelial 
CL import pump.
CBD peptide blocks CL uptake and lung injury
We mapped the ATP8b1-CL binding domain (CBD). Synthesized deletion mutants 
(Supplementary Fig. 7a,b) were reacted with fifteen lipids pre-spotted onto hydrophobic 
lipid strips (Supplementary Fig. 7c). Using this system, FL ATP8b1 and specific mutants 
were observed to bind CL and also sulfatide (Supplementary Fig. 7c). C–terminal truncation 
mutants containing only the first 810 or 771 residues did not bind CL suggesting that a CBD 
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resides between residues 810 to 850 within ATP8b1. This was confirmed by testing a 
fragment (residues 771-850) that was sufficient for CL binding indicating that a novel CBD 
resides within the ATP8b1 carboxyl-terminus (Supplementary Fig. 7c).
A cDNA encoding the putative CBD was fused to GST, for expression of purified protein 
from cells. Cells cultured with GST-CBD peptide exhibited an 83% decrease in [3H] CL 
uptake versus GST peptide alone (Fig. 6a). Mice infected with or without E. coli and given 
CBD peptide compared to vehicle exhibited a significantly increased proportion of 
macrophages and modestly reduced protein content and BAL neutrophils (Supplementary 
Fig. 8a,b). Importantly, CBD peptide profoundly reduced TNF-α, and IL-β levels and 
significantly reduced GM-CSF levels after bacterial infection (Fig 6, Supplementary Fig. 
8c). CBD peptide did not alter surfactant apoproteins nor the degree of apoptosis 
(Supplementary Fig. 9a,c). Infected mice given vehicle exhibited impaired lung mechanics, 
effects that were reversed after CBD peptide administration (Fig. 6b,c,d, Supplementary Fig. 
9b). These beneficial effects of CBD peptide on pulmonary homeostasis led to significantly 
improved survival in mice (Fig. 6f). Thus, the CBD within ATP8b1 is functional with regard 
to substrate binding and this peptide exerts biological effects in concert with its activity in 
antagonizing actions of CL in vivo.
Discussion
Pneumonia remains a major public health challenge and a major cause of intensive care unit 
admission. Antimicrobial agents remains the cornerstone of therapy for bacterial pneumonia 
but few non-antibiotic therapies have emerged that impact outcomes of patients with severe 
infection. The data here provides a new conceptual model involving CL as mediator of 
pneumonia and its trafficking by ATP8b1. We show that CL is significantly elevated both in 
human subjects with pneumonia and in mice infected with bacterial pathogens. CL potently 
impairs lung mechanics by antagonizing surfactant function leading to high surface-tension 
pulmonary edema (Figs. 2a, Fig.3b,c)16,17. CL was also observed to disrupt pulmonary 
architecture and reduce epithelial cell viability. Our finding that adverse effects of CL are 
antagonized by CL binding peptide suggest that future studies might entail use of small 
molecule modifiers that regulate CL availability as novel non-antibiotic treatment strategies 
for patients with pneumonia.
Because CL is an apoptotic cell surface marker and a constituent of bacterial membranes, it 
is plausible that its release in lung fluid during pneumonia represents infections having very 
high bacterial burdens. CL content in some bacterial envelopes, such as E. coli, is very high 
but it is undetectable in H. influenzae membranes 18,19. Yet both pathogens reduced CL 
uptake (Fig. 1c) and increased CL concentrations (Fig. 1b) suggesting other mechanisms for 
its origin. One possibility is that CL, normally exclusively present within the inner 
mitochondrial membrane, is released from dying host cells, particularly during execution of 
intrinsic mitochondria-dependent apoptosis. Early in the programmed cell death, CL 
transmigrates to the outer mitochondrial membrane 20 and can also reach the outer leaflet of 
the cell’s plasma membrane 21 where it could be readily integrated in surfactant. Because 
molecular signatures of CL species differ between mammalian cells and bacterial 
membranes, we examined the source of CL in pneumonia patients (Supplementary Fig.10a) 
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and mice infected with E. coli (Supplementary Fig. 10b). Indeed, ESI-MS spectra of CLs 
obtained from human and mouse samples demonstrate that CL originates from mammalian 
cells. Hence mitochondria-specific mammalian species of CL - not bacterial - were found in 
lung fluid samples. These results do not totally exclude a bacterial origin, as bacterial CL 
elevation in fluid may be transient or prokaryotic organisms might utilize host cell 
mitochondrial CL that is incorporated into bacterial membranes. Last, host (type II cell) 
apoptosis could lead to reduced surfactant production independently from effects of CL.
CL is highly effective in inhibiting surfactant activity. CL was twice as potent as 
lysophosphatidylcholine, a gold standard reference 22. Optimal surfactant activity depends 
on tight molecular packing of the major surfactant phospholipid, dipalmitoyl-
phosphatidylcholine (DPPC), within a film at the air-surface interface. CL’s ability to block 
surface-tension lowering by DPPC would be predicted because of its bulky molecular 
structure that would impede DPPC packing. It is difficult to equate CL concentrations in 
human tracheal aspirates (Fig. 1a) with pathophysiologic levels of CL incorporated into the 
DPPC film in human BAL fluid. This is because of significant issues of recovery, sample 
dilution, and tight binding of CL with mitochondrial proteins reducing its extraction 23. 
However, inhibitory actions of CL were seen even at very low concentrations (~ 2 Mol%) 
(Fig. 2b) using CL liposomes devoid of surfactant apoproteins 3. Thus, surfactant proteins 
may protect against CL inhibition and adverse CL effects may be more pronounced when 
surfactant proteins are depleted 24. When CL was added as liposomes with apoproteins, 
surface-tension was markedly elevated (Fig. 2a). Here, higher concentrations of CL (at 5-20 
Mol%) as seen in pneumonia patients are needed to impair surface-activity. The data suggest 
that CL concentrations that impair surface-activity are within the pathophysiologic range. 
These observations need to be confirmed in larger studies adjusted for important factors 
(smoking status, illness severity, lung compliance, and comorbidities) as the current results 
in tracheal aspirates are associative and lack important measures such as cell counts and 
proteins, and were not adjusted for dilution. The use of BAL or Mini-BAL may further 
strengthen these associations by improving the accuracy of pneumonia diagnosis and 
adjusting for inflammatory markers. Subgroup CL analysis (e.g. alveolar hemorrhage and 
stages of acute lung injury) are also essential in understanding these associations. Serial 
measurements during mechanical ventilation may better link tracheal colonization and 
resolving inflammation with CL levels in tracheal aspirates.
Alveolar cells harbor active transport mechanisms to maintain very low CL concentrations 
typically seen in human lavage fluid 25,26. Evidence in support of ATP8b1 as an authentic 
CL import protein include that (i) ATP8b1 binds CL within a highly charged inter-
transmembrane domain loop, (ii) in vivo administration of a peptide containing this putative 
CBD signature or Ad5-ATP8b1 gene transfer lowers CL levels coupled with reduced lung 
injury severity, and (iii) ATP8b1 defective mice have increased CL levels and are vulnerable 
to bacterial-induced lung injury. The data might suggest that CL elaborated during 
pulmonary infection exceeds the substrate binding capacity by ATP8b1. Here, bacteria could 
down-regulate ATP8b1 expression, mask the CL-binding pocket by inducing ATP8b1 
conformational changes, or reduce pump catalytic function. In this regard, H. influenzae 
triggers ATP8b1 degradation and ubiquitination (Supplementary Fig. 11). Presumably, 
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redundant mechanisms for CL import are insufficient as ATP8b1 mutant mice displayed 
sensitivity to pulmonary sepsis. Other related ATP-driven pumps, ATP8a1 and ATP11a, did 
not transport CL (Supplementary Fig. 12).
These studies are the first demonstrating cellular uptake of CL via protein binding. The 
ATP8b1-CL binding domain (CBD) was mapped to a 40 residue motif within a predicted 
inter-transmembrane loop 2728 (Supplementary Fig. 7). This loop contains several regulatory 
elements including a D554N missense mutation seen in PFIC1 patients 28. As PFIC1 
patients have a higher incidence of respiratory symptoms there may be additional 
polymorphisms within the CBD that predisposes patients to infection. Administration of 
CBD peptide in mice significantly lessened pulmonary impairment after infection 
suggesting that the molecular interactions between the ATP8b1 motif and CL are preserved 
in vivo. Manipulation of CL appears to modulate the inflammatory response (Supplementary 
Fig. 8, Fig.6) and CL inhibits key cell survival pathways, effects blocked by CBD peptide 
(Supplementary Fig.13). Thus, alveolar CL and the peptide appear to exert 
immunomodulatory actions that could affect resolution of pulmonary injury. These results 
might eventually serve as a springboard to generate drug therapies to sequester or enhance 
clearance of injurious CL in pneumonia.
Methods
Human samples
The study was approved by respective institutional review boards. After obtaining informed 
consent, tracheal aspirates were collected using an inline suction catheter without saline 
dilution. Patients were diagnosed with pneumonia (clinical diagnosis and confirmed with 
infiltrates on chest x-ray), CHF (clinical diagnosis and confirmed with pulmonary edema on 
chest x-ray) and included control subjects who were intubated for non-pulmonary illnesses 
(normal chest x-ray). Aliquots were sent for routine cultures.
Cells
Mouse lung epithelial (MLE) cells were cultured as described 32. Cells were serum starved 
for 24 h then exposed to 120 nmol/ml Infasurf, PC liposomes, or CL (5-15 Mol %). Mouse 
alveolar type II cells, macrophages, and fibroblasts were isolated as described 32. Cell 
viability was determined using the CellTiter-Glo Luminescent Cell Viability assay 
(Promega). LDH release was assayed by monitoring the NAD-NADH reaction at a 340 nm 
wavelength.
[3H]-CL uptake
[3H]- CL (Moravek Biochemicals, Inc.) was reconstituted in liposomes using Infasurf 
(Forest Pharmaceuticals Inc.) and added to medium for 2 h at 37 °C. Cellular uptake was 
terminated by washing with serum-free cold media twice and 2% fatty acid free BSA in 
PBS. Lipids were extracted (1 ml hexane:isopropanol (3:2, v/v)), solvents dried, and 
radioactivity (dpm) in lipids measured by scintillation counting.
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FL ATP8b1 was amplified from an expression clone in pcDNA3.1D/V5-His using a forward 
and reverse primer with engineered EcoRI or SpeI restriction sites, respectively. The 
amplified product was directionally cloned into the EcoRI and BamHI sites of the 
adenovirus shuttle plasmid, pacAd5 CMV K-NpA. An adenovirus expression vector 
including V5-FL ATP8b1 was produced by the University of Iowa Gene Transfer Vector 
Core 33.
Mice
C57BL/6 mice (Jackson Laboratories) were used according to Institutional Animal Care and 
Use Committee approved protocols. E. coli (ATCC 25922) (1 ×106 CFU (colony forming 
units)) was administered intratracheally (i.t). Mice were infected i.t. (2 ×108 CFU, 
nontypable H. influenzae) or given agarose 29 for 72 h prior to lung lavage. For adenoviral 
gene transfer, mice received 2.5 ×108 PFU (plaque forming units) i.t. and 24 h later given E. 
coli for 48 h. Mice were mechanically ventilated with a FlexiVent system 34. Mice were also 
given E. coli, ventilated, and 48 h later diluent or ATP8b1 CBD peptide was delivered into 
lungs using a microsprayer aerosolizer. After 10 min, biophysical measurements were taken. 
For assay of lung edema, mice received CL (15 mM in 50 μl saline i.t.) or vehicle (50 μl 
saline). Evan’s Blue dye (40 μg/g in 100 μl saline) was injected intravenously via the 
femoral vein 30 min later, BAL was obtained, Dye concentration was determined using a 
spectrophotometer at a wavelength of 620 nm. For wet/dry weights lungs were removed, 
blotted, and placed in tared weigh boats and weighed. The lungs were then dried (24 h at 60 
°C) and weighed again.
Fluorescent microscopy
Cells were plated (35 mm culture dishes) and incubated with NBD-CL and NBD-PS (25 
°C), and then immediately incubated at 4 °C for 5 min prior to washing with medium. 
Fluorescence was detected using an epifluorescent microscope (Olympus).
Lentiviral stable cell line
Lentivirus expressing ATP8b1 was produced using pLenti6/V5-DEST by the University of 
Iowa Gene Transfer Vector Core. Cells were transduced with a final concentration of 4 
μg/ml of polybrene (Sigma) in MEM-F12, at a multiplicity of transduction of 10:1. A final 
concentration of 2.5 μg/ml blasticidin (Invitrogen) was used to select for transduced cells.
NBD-lipid uptake
NBD-labeled phosphatidylserine (PS) (Avanti Polar Lipids, Inc.) and NBD- CL (Invitrogen) 
were incubated with cells for 30 min at 37 °C. Lipids were extracted twice with 1 ml 
hexane:isopropanol (3:2, v/v). The solvents were evaporated under nitrogen and lipids 
dissolved in methanol. The fluorescence of NBD-labeled lipids was measured (excitation 
and emission at 460/530 nm) and quantitated using standard curves for known amounts of 
the NBD-labeled lipids.
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Lipids were extracted 35,36 and CL bound to fluorescent nonyl acridine orange (NAO) was 
quantitated using a spectrophotometer measuring NAO excitation and emission (494/530 
nm) using standard curves 37. Values were normalized for total phospholipid phosphorus 38 
and expressed as ratios (Mol%) of phosphorus (nmol) in CL to total phospholipid (nmol) 
within samples.
Lipid overlay
Lipid strips (Echelon Biosciences, Inc.) were incubated with translation products in TTBS 
buffer with 1% fatty acid-free BSA. Strips were washed extensively and radiolabeled protein 
was detected with V5 antibody using immunoblotting.
ATP8b1 knockdown
A549 alveolar type II (ATII) cells were transfected twice with 2 μg of ATP8b1 ON 
TARGET plus SMARTpool siRNA or ON-TARGET plus Non-targeting Pool control 
siRNA (Dharmacon) for 48 h using Fugene 6 prior to harvest.
Statistical Analysis
We used a Prism program version 4.03 (GraphPad Software, Inc.) using an ANOVA or 
unpaired t test with P<0.05 indicative of significance. Kaplan Meier survival estimates were 
done using SAS version 9.2 (SAS institute). For human data, nonparametric testing using a 
Kruskal-Wallis and post hoc Wilcoxon rank sum test was performed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Quantification of cardiolipin (CL) in pneumonia
a. Panel a depicts the median (gray line) and distribution (black circles) of CL levels in 
tracheal aspirates from subjects with non-pulmonary critical illness (NPCI, n=five), 
pneumonia (PNA, n=17), and congestive heart failure (CHF, n=six). Groups were compared 
by Kruskal Wallis test (P=0.0007) followed by post hoc Wilcoxon Rank Sum analysis with 
Bonferroni correction for multiple testing b. C57BL/6 mice (three control, five H. 
influenzae, four E.coli) were infected intratracheally (i.t.) with E. coli (1 ×106 CFU/mouse) 
or H. influenzae (2 × 108 CFU/mouse). Mice were euthanized 48 h (E. coli) or 72 h (H. 
influenzae) later, lungs lavaged, and processed for CL assay. Inset: Mice (six/group) were 
given HCL (pH 1.5, 2 ml/kg i.t.) prior to being euthanized 30 min later for analysis of CL. c. 
Primary type II lung epithelia (from n=ten mice) were cultured with [3H]-CL containing the 
commercial surfactant, Infasurf, for 2 h at 37 °C in the presence or absence of E. coli 
(MOI=100) or H. influenzae (MOI=10) and cellular CL uptake was determined. In (b-c), ** 
represents means ± S.D. with P<0.01, and ***represents P<0.001 vs. control as determined 
by one-way ANOVA analysis.
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Figure 2. Biophysical effects of CL. a-b. Surface-tension
Cardiolipin (CL), lysophosphatidylcholine (LPC), and phosphatidylserine (PS) were 
reconstituted with Infasurf (liposomes in CaCl2 (5 mM)) with apoprotein (a) or without 
apoprotein (b) and dynamic surface tension (γmin) was measured using a pulsating bubble 
surfactometer. Increasing amounts of CL in Infasurf resulted in significantly increased 
surface tension compared to LPC or PS (magnified in inset). c-f. Mice (three-five/group) 
were anesthetized, paralyzed, and mechanically ventilated with a PEEP=3 and compliance 
(c), quasi-static pressure-volume curves (d), elastance (e), and resistance (f) was determined 
using a FlexiVent system after i.t. application of phosphatidylglycerol (PG) or CL. 
Significance was determined by a one-way ANOVA analysis 
where *P<0.05, *P<0.01, ***P<0.001 vs. control.
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Figure 3. CL disrupts lung structure and alters epithelial cell viability
a. MicroCT scan images were obtained on live mice (in vivo) 1 h after i.t. administration of 
CL (50 nmole, [low], 100 nmole [high]) vs. control mice (above panels). In separate studies, 
mice were given CL as above and lungs were fixed and processed for microCT scanning (ex 
vivo). Data represents two mice/group. Below, third row: fixed tissue was processed for H & 
E staining (20× magnification). Lower row (middle) shows a high magnification (100×) 
image of foamy cells. b-c. CL induces lung edema. Mice were deeply anesthetized and 
administered CL (15 mM in 50 μl saline, i.t.; n = three) or vehicle (50 μl saline; n = 3). 30 
min after CL administration Evan’s Blue dye was injected intravenously. Wet/dry weights of 
lungs were also determined (c). ***P<0.01 vs. control. d. Primary mouse type II cells were 
serum starved for 24 h and then exposed to Infasurf (120 nmol/ml) or CL (5-15 Mol%) for 
various times prior to harvest for detection of poly(ADP-ribose) polymerase (PARP) 
cleavage (d, arrows, left panel); mice were also given i.t. CL (50 nmol) for analysis of lung 
DNA fragmentation using a DNA ladder extraction kit ([BioVision], d, right panel) or 
assayed for cell viability (e) and LDH release (f, primary type II cells). NP-40 was used as a 
positive control for LDH release. Data represents three separate experiments 
where *P<0.05, **P<0.01, and ***P<0.001 vs. control as determined by one-way ANOVA 
analysis.
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Figure 4. ATP8b1 overexpression
a-c. A lentiviral transduced V5-ATP8b1 stable cell line was labeled with NBD-CL or NBD-
PS and cells were processed for fluorescence uptake by time-lapse microscopy. The 
lentiviral transduced ATP8b1 cell line exhibited increased uptake of NBD-labeled CL and 
NBD-labeled PS compared to untransduced control cells as quantitated by fluorescence 
spectrophotometry in (b). **P<0.05 and *** P<0.001 by an unpaired t test. c-d. Mice (eight/
group) received an empty vector (Ad5) or Ad5-ATP8b1 (2.5 ×108 PFU) i.t. and 24 h later 
given E. coli at 106 CFU/mouse for 48 h. Animals were anesthetized, paralyzed and 
mechanically ventilated and lung mechanics determined as in Fig. 2. The data in (c) top 
panel is a representative immunoblot showing levels of V5-immunoreactive ATP8b1 in lung 
tissue from two mice receiving Ad5 or Ad5-ATP8b1. In (d) CL levels were assayed in BAL 
after Ad5-ATP8b1 or Ad5 infection. Significance was determined by a one-way ANOVA 
where in (c) and (d) *P<0.05 for empty + E. coli vs. other groups. e. Mice treated as in (c) 
were also analyzed for lung DNA fragmentation. f. Kaplan-Meier survival curve for mice 
infected with Ad5 empty or Ad5-ATP8b1 and infected with E. coli. (5 × 106 cfu/mouse, 
n=14 mice/group, P<0.001, log rank test).
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Figure 5. ATP8b1 defective mice are prone to bacterial-induced lung injury
a. ATP8b1 siRNA knockdown. Human A549 ATII cells were transfected with ATP8b1 
siRNA or control RNA and incubated with NBD-labeled CL or PS for 30 min at 37 °C prior 
to harvest for uptake (left) and immunoblotting (right) using 25 μg of protein loaded/lane. 
Blots were probed with ATP8b1, LPCAT1, Erk1, importin-α, and β-actin 
antibodies. **P<0.01. b. ATP8b1G308V/G308V mutants genomic DNA has a Hae III 
restriction site (GGCC) in which the second G is mutated to T (glycine to valine) and is not 
recognized in restriction digests. Mutant genomic DNA generates an 800 bp fragment upon 
HaeIII digestion compared to a 500 bp fragment with wild-type genomic DNA. The HaeIII 
digestion pattern was used for genotyping wild-type (Wt), heterozygous (Het), and mutant 
(Mut) mice. c. ATP8b1 immunoblotting in mouse tissues. Below: densitometric analysis 
from n=six mice/group. d. CL was assayed in lung lavage from ATP8b1 mutant and wild-
type littermates (three/group). **P<0.01. e. Primary type II epithelia isolated from mutants 
or wild-type littermates (five mice/group) were incubated with NBD-CL and cellular uptake 
was assayed initially after labeling (t=0) and after 1 min. f-g. Mutants and wild-type 
littermates uninfected or infected (seven/group) with E. coli at 106 CFU/mouse for 48 h 
were analyzed for lung mechanics. Mice were mechanically ventilated for determination of 
quasi-static volume-pressure curves (f, [uninfected]), and elastance (g). Statistical 
significance was determined by a one-way ANOVA where in (g) ** WT vs. MUT + E.coli, 
P<0.01 and * WT+ E. coli vs. MUT+ E. coli, P<0.05. h. Wild type and mutant mice treated 
as in (g) were also analyzed for lung DNA fragmentation. i. Kaplan-Meier survival curve for 
wild-type and ATP8b1 defective mice infected with E. coli, (5 × 106 CFU/mouse, seven 
mice/group, P=0.11, log rank test).
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Figure 6. Cardiolipin binding domain (CBD) peptide blocks bacterial lung injury
a. ATP8b1 CBD-GST fusion peptide (CBD) or GST (control) were purified and incubated 
with MLE cells (10 μg of GST peptide or GST-CBD peptide/dish) in serum-free medium 
after labeling for 2 h with [3H]-CL. Cells were harvested and processed for cellular [3H]-CL 
uptake, **P<0.01. b-d. C57/BL6 mice (six mice/group) were uninfected (control) or given 
E. coli at 106 CFU/mouse. After 48 h, mice were given vehicle, or CBD peptide into lungs 
using an aerosolizer. After 10 min, biophysical measurements were taken. Mice were 
mechanically ventilated for determination of quasi-static volume-pressure curves (b), 
compliance (c), and elastance (d). Significance was determined by a one-way ANOVA 
where in panel (c) *** P<0.001 vehicle vs. all other groups, (d) * P<0.05 for 25 μg vs. either 
control or vehicle and *** P<0.001 vehicle vs. control, 100 μg, or 250 μg. (e). Mice (n=four/
group) were inoculated with 1 × 106 CFU E. coli or uninfected for 48 h prior to i.t. 
administration of CBD. Mice were lavaged, and BAL supernatant assayed for cytokines. All 
P values are <0.05 for vehicle buffer + E. coli. (0+) vs. other groups. f. Kaplan-Meier 
survival curve for mice given i.t. CBD peptide (100 μg) and infected with E. coli, (5 × 106 
CFU/mouse, n=14 mice/group, P=0.001, log rank test).
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